The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early safety and efficacy from a phase I open-label clinical study of LVGN7409 (CD40 agonist antibody) in patients with advanced or metastatic malignancies.
 
Siqing Fu
Research Funding - Abbisko (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); Exelis (Inst); Exelis (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); K-Group Beta (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); Millennium (Inst); NCCN (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Parexel International, LLC (Inst); PureTech (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Vaccibody (Inst)
 
Andrae Lavon Vandross
No Relationships to Disclose
 
Yi Hsin Hsu
No Relationships to Disclose
 
Naiyi Shi
No Relationships to Disclose
 
Lynn Jiang
Employment - Lyvgen Biopharma
 
Fusheng Su
Employment - Lyvgen Biopharma
Consulting or Advisory Role - Lyvgen Biopharma
 
Jieyi Wang
Employment - Lyvgen Biopharma
Stock and Other Ownership Interests - Lyvgen Biopharma
 
C. Hubert Chan
Employment - Henlius; Lyvgen Biopharma; PharmaEngine
Stock and Other Ownership Interests - PharmaEngine